RT Journal Article
T1 Assessing the impact of COVID-19 on liver cancer management (CERO-19).
A1 Muñoz-Martinez, Sergio
A1 Sapena, Victor
A1 Forner, Alejandro
A1 Nault, Jean-Charles
A1 Sapisochin, Gonzalo
A1 Rimassa, Lorenza
A1 Sangro, Bruno
A1 Bruix, Jordi
A1 Sanduzzi-Zamparelli, Marco
A1 Hołowko, Wacław
A1 El-Kassas, Mohamed
A1 Mocan, Tudor
A1 Bouattour, Mohamed
A1 Merle, Philippe
A1 Hoogwater, Frederik J H
A1 Alqahtani, Saleh A
A1 Reeves, Helen L
A1 Pinato, David J
A1 Giorgakis, Emmanouil
A1 Meyer, Tim
A1 Villadsen, Gerda Elisabeth
A1 Wege, Henning
A1 Salati, Massimiliano
A1 Mínguez, Beatriz
A1 Di-Costanzo, Giovan Giuseppe
A1 Roderburg, Christoph
A1 Tacke, Frank
A1 Varela, María
A1 Galle, Peter R
A1 Alvares-da-Silva, Mario Reis
A1 Trojan, Jörg
A1 Bridgewater, John
A1 Cabibbo, Giuseppe
A1 Toso, Christian
A1 Lachenmayer, Anja
A1 Casadei-Gardini, Andrea
A1 Toyoda, Hidenori
A1 Lüdde, Tom
A1 Villani, Rosanna
A1 Matilla-Peña, Ana Maria
A1 Guedes-Leal, Cassia Regina
A1 Ronzoni, Monica
A1 Delgado, Manuel
A1 Perello, Christie
A1 Pascual, Sonia
A1 Lledo, Jose Luis
A1 Argemi, Josepmaria
A1 Basu, Bristi
A1 da-Fonseca, Leonardo
A1 Acevedo, Juan
A1 Siebenhüner, Alexander R
A1 Braconi, Chiara
A1 Meyers, Brandon M
A1 Granito, Alessandro
A1 Sala, Margarita
A1 Rodriguez-Lope, Carlos
A1 Blaise, Lorraine
A1 Romero-Gomez, Manuel
A1 Piñero, Federico
A1 Gomez, Dhanny
A1 Mello, Vivianne
A1 Pinheiro-Alves, Rogerio Camargo
A1 França, Alex
A1 Branco, Fernanda
A1 Brandi, Giovanni
A1 Pereira, Gustavo
A1 Coll, Susanna
A1 Guarino, Maria
A1 Benítez, Carlos
A1 Anders, Maria Margarita
A1 Bandi, Juan C
A1 Vergara, Mercedes
A1 Calvo, Mariona
A1 Peck-Radosavljevic, Markus
A1 Garcia-Juarez, Ignacio
A1 Cardinale, Vincenzo
A1 Lozano, Mar
A1 Gambato, Martina
A1 Okolicsanyi, Stefano
A1 Morales-Arraez, Dalia
A1 Elvevi, Alessandra
A1 Muñoz, Alberto E
A1 Lue, Alberto
A1 Iavarone, Massimo
A1 Reig, Maria
K1 BCLC, Barcelona Clinic Liver Cancer
K1 CERO-19, Liver Cancer Outcome in the COVID-19-pandemic Project
K1 COVID-19
K1 COVID-19, coronavirus disease 2019
K1 Cholangiocarcinoma
K1 Clinical trials
K1 ENS-CCA, European Network for the Study of Cholangiocarcinoma
K1 HCC, hepatocellular carcinoma
K1 Hepatocellular carcinoma
K1 LC, liver cancer
K1 LT, liver transplantation
K1 Liver cancer
K1 Management
K1 Nurses
K1 SARS-CoV-2, severe acute respiratory syndrome coronavirus-2
K1 iCCA, intrahepatic cholangiocarcinoma
AB The coronavirus disease 2019 (COVID-19) pandemic has posed unprecedented challenges to healthcare systems and it may have heavily impacted patients with liver cancer (LC). Herein, we evaluated whether the schedule of LC screening or procedures has been interrupted or delayed because of the COVID-19 pandemic. An international survey evaluated the impact of the COVID-19 pandemic on clinical practice and clinical trials from March 2020 to June 2020, as the first phase of a multicentre, international, and observational project. The focus was on patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma, cared for around the world during the first COVID-19 pandemic wave. Ninety-one centres expressed interest to participate and 76 were included in the analysis, from Europe, South America, North America, Asia, and Africa (73.7%, 17.1%, 5.3%, 2.6%, and 1.3% per continent, respectively). Eighty-seven percent of the centres modified their clinical practice: 40.8% the diagnostic procedures, 80.9% the screening programme, 50% cancelled curative and/or palliative treatments for LC, and 41.7% modified the liver transplantation programme. Forty-five out of 69 (65.2%) centres in which clinical trials were running modified their treatments in that setting, but 58.1% were able to recruit new patients. The phone call service was modified in 51.4% of centres which had this service before the COVID-19 pandemic (n = 19/37). The first wave of the COVID-19 pandemic had a tremendous impact on the routine care of patients with liver cancer. Modifications in screening, diagnostic, and treatment algorithms may have significantly impaired the outcome of patients. Ongoing data collection and future analyses will report the benefits and disadvantages of the strategies implemented, aiding future decision-making. The coronavirus disease 2019 (COVID-19) pandemic has posed unprecedented challenges to healthcare systems globally. Herein, we assessed the impact of the first wave pandemic on patients with liver cancer and found that routine care for these patients has been majorly disrupted, which could have a significant impact on outcomes.
PB Elsevier BV
YR 2021
FD 2021-02-23
LK http://hdl.handle.net/10668/17255
UL http://hdl.handle.net/10668/17255
LA en
NO Muñoz-Martínez S, Sapena V, Forner A, Nault JC, Sapisochin G, Rimassa L, et al. Assessing the impact of COVID-19 on liver cancer management (CERO-19). JHEP Rep. 2021 Jun;3(3):100260.
DS RISalud
RD Apr 18, 2025